CAS: 1611493-60-7; (2R,5S,13Ar)-8-Hydroxy-7,9-Dioxo-N-(2,4,6-Trifluorobenzyl)-2,3,4,5,7,9,13,13A-Octahydro-2,5-Methanopyrido[1',2':4,5]Pyrazino[2,1-B][1,3]Oxazepine-10-Carboxamide

该化合物是治疗艾滋病毒-1感染过程中使用的强效整治性沙粒转移抑制剂,其主要优势包括抗病毒功效高,抗药性强,抗药性强以及由于代谢干扰低而药物-药物相互作用最小.比克格拉维通常与其他抗逆转录病毒药物(如乳汁碱和花生植物)结合配制,以提供一种一次性的一次性一次性治疗.其强健的药理学特性确保了持续的治疗浓度,加强了患者的坚持性.复合物显示出与艾滋病毒-1抗逆转录病毒的紧密结合,有效地阻止病毒DNA融入宿主基因组.比克格拉维的安全性和耐性使得它成为现代抗逆转录病毒疗法的首选方案.

结构式图片

上下游产品

(2R,5S,13aR)-8-methoxy-7,9-dioxo-2,3,4,5,7,9,13,13a-°Ctahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid (2R,5S,13aR)-8-methoxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3,4,5,7,9,13,13a-°Ctahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide 1-(2,2-dihydroxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid 1-[2,2-bis(methyloxy)ethyl]-5-(methyloxy)-6-[(methyloxy)carbonyl]-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid

合成工艺路线路线简述

  • 合成目标产物 Bictegravir 主要起始原料 (2R,5S,13Ar)-8-Methoxy-7,9-Dioxo-N-(2,4,6-Trifluorobenzyl)-2,3,4,5,7,9,13,13A-Octahydro-2,5-Methanopyrido[1',2':4,5]Pyrazino[2,1-B][1,3]Oxazepine-10-Carboxamide
  • (文献来源)合成步骤主要原料 (2R,5S,13Ar)-8-Methoxy-7,9-Dioxo-N-(2,4,6-Trifluorobenzyl)-2,3,4,5,7,9,13,13A-Octahydro-2,5-Methanopyrido[1',2':4,5]Pyrazino[2,1-B][1,3]Oxazepine-10-Carboxamide
Lithium (2R,5S,13Ar)-7,9-Dioxo-10-((2,4,6-Trifluorobenzyl)Carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1',2':4,5]Pyrazino[2,1-B][1,3]Oxazepin-8-Olate置于盐酸体系中,用 甲醇,水 用作溶剂,化学反应 1.0H,以78%的收率获得比卡格韦
参考文献: Process For The Preparation Of Sodium (2R,5S,13Ar)-7,9-Dioxo-10-((2,4,6-Trifluorobenzyl)Carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1',2':4,5]Pyrazino[2,1-B] [1,3] Oxazepin-8-Olate And Its Polymorphic Form[fr] Procédé De Préparation De (2R,5S,13Ar)-7,9-Dioxo-10-((2,4,6-Trifluorobenzyl)Carbamoyl)-2,3,4,5,7,9,13,13 A-octahydro-2,5-Méthanopyrido[1',2': 4,5]Pyrazino[2,1-B][1,3]Oxazépin-8-Olate Et Sa Forme Polymorphe
标题: Process For The Preparation Of Sodium (2R,5S,13Ar)-7,9-Dioxo-10-((2,4,6-Trifluorobenzyl)Carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1',2':4,5]Pyrazino[2,1-B] [1,3] Oxazepin-8-Olate And Its Polymorphic Form[fr] Procédé De Préparation De (2R,5S,13Ar)-7,9-Dioxo-10-((2,4,6-Trifluorobenzyl)Carbamoyl)-2,3,4,5,7,9,13,13 A-octahydro-2,5-Méthanopyrido[1',2': 4,5]Pyrazino[2,1-B][1,3]Oxazépin-8-Olate Et Sa Forme Polymorphe
摘要:本发明涉及一种制备化合物i的工艺,化合物i为钠(2R,5S,13Ar)-7,9-二氧基-10-((2,4,6-三氟苯甲基)氨基甲酰)-2,3,4,5,7,9,13,13A-八氢-2,5-甲基吡啶[1',2':4,5]吡嗪[2,1-B][1,3]噁唑-8-酸盐及其多晶形式.

海关参考信息

专利信息


专利号:US-2024067621-A1
优先权日:2021-02-23
标 题:Polyfluorinated cannabinoid and cannabinoid-like compounds and methods of synthesis and use thereof
发明人:WEAVER JIMMIE D; DAY JON; GROTJAHN SASCHA; SENAWEERA SAMEERA; KOENIG BURKHARD
权利人:WEAVER JIMMIE D; DAY JON; GROTJAHN SASCHA; SENAWEERA SAMEERA; KOENIG BURKHARD; THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES
摘要:Polyfluorinated compounds are disclosed, including polyfluorinated cannabinoid and cannabinoid-like compounds. Also disclosed are methods of producing the polyfluorinated compounds.

专利号:WO-2018229798-A1
优先权日:2017-06-13
标题 :Process for the preparation of bictegravir and intermediate thereof
发明人:PHULL MANJINDER SINGH; RAO DHARMARAJ RAMACHANDRA; BIRARI DILIP RAMDAS
权利人:CIPLA LTD
摘要:The present invention provides processes and intermediates for the synthesis of bictegravir and its pharmaceutical salt.

专利号:US-11248005-B2
优先权日:2019-07-08
标 题 :Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
发明人:JADHAV HARISHCHANDRA SAMBHAJI; SHRIVASTAVA DHANANJAI; AHER UMESH PARASHARAM; DEOKAR SHARAD CHANDRABHAN; NALE DEEPAK BABASAHEB; HONRAO SURYAKANT TUKARAM; SINGH GIRIJ PAL
权利人:LUPIN LTD
摘要:Provided herein is a process for the intermediates used for preparation of HIV Integrase Inhibitor such as Bictegravir, Dolutegravir, Cabotegravir or their pharmaceutically acceptable salts.

专利号:US-10745342-B2
优先权日:2018-07-05
标 题 :Synthesis method of 2,4,6-trifluorobenzylamine
发明人:YUAN QILIANG; QIAN JIE; LAI XIN; CHEN HAIFENG; CHEN YINHAO; WANG CHAO
权利人:ZHEJIANG ZHONGXIN FLUORIDE MAT CO LTD; SHAOXING ZHONGKE BAIYUN CHEMICAL TECH CO LTD
摘要:The disclosure provides a synthesis method of 2,4,6-trifluorobenzylamine, belonging to the technical field of chemical synthesis. The synthesis method is characterized by comprising the following steps: (1) allowing pentachlorobenzonitrile as a raw material to undergo fluoridation reaction with a fluoridation agent based on 2,4,6-trifluoro-3,5-dichlorobenzonitrile as a solvent to obtain 2,4,6-trifluoro-3,5-dichlorobenzonitrile; (2) hydrogenating the obtained 2,4,6-trifluoro-3,5-dichlorobenzonitrile with hydrogen in the presence of organic carboxylic acid, based, on palladium carbon as a catalyst to obtain 2,4,6-trifluoro-3,5-dichlorobenzylamine; and (3) hydrogenating the obtained 2,4,6-trifluoro-3,5-dichlorobenzylamine with hydrogen in a solvent in the presence of a catalyst to obtain 2,4,6-trifluorobenzylamine. The synthesis method has the advantages of low raw material cost, short reaction steps, high reaction yield, good product purity simple operation and the like, and is suitable for industrial production.

专利号:US-2021009606-A1
优先权日:2019-07-08
标题:Process for Preparation of Intermediates Used for the Synthesis of HIV Integrase Inhibitor

专利号:WO-2022182623-A1
优先权日:2021-02-23
标 题 :Polyfluorinated dicyclic compounds and methods of synthesis thereof
上海迪赛诺医药集团股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.desano.com
电话: 021-51323300👤
📞上海迪赛诺医药集团股份有限公司 ⚠️参考联系方式

销售电话:021-51323300
邮箱:info@desano.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
常州远大医药化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.ydpharm.com
企业联系电话:0519-88776993;83984084👤
📞常州远大医药化工有限公司 ⚠️参考联系方式
联系人:朱经理;袁经理
电话:0519-88776993;83984084
手机:13776846168;18118019798
传真:0519-88776993
邮箱:sales@ydpharm.com
通信地址: 常州市新北区罗溪镇塑化路25号
邮编: 213033
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:常州市新北区罗溪镇塑化路25号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Tiraboschi J, Imaz A, Khoo S, Niubo J, Prieto P, Saumoy M, Penchala SD, Garcia B, Padilla C, Videla S, Podzamczer D. Total and Unbound Bictegravir Concentrations and Viral Suppression in CSF of HIV-infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56). J Infect Dis. 2019 Nov 30. pii: jiz624. doi: 10.1093/infdis/jiz624. [Epub ahead of print] Available from http://www.ncbi.nlm.nih.gov/books/NBK547914/ doi: 10.1097/QAI.0000000000002137. doi: 10.1093/jac/dkz412.
5: Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347.
6: Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5. doi: 10.1016/S2352-3018(19)30135-3. Epub 2019 May 5. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5. doi: 10.18773/austprescr.2019.016. Epub 2019 Feb 28. Review.

合成参考文献


摘要:[L1221]
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知